Neuropsychiatric patient care and clinical trial outcomes are less connected to underlying physiological causes than any other branch of medicine. We predict treatment response by analyzing relationships between neurophysiological signals and symptoms to reduce clinical trial failure rates and advance beyond the current “trial-and-error” state of neuropsychiatric care. Our vertically integrated iMAGiNE™ platform aggregates and synthesizes multimodal neural, physiological, and multi-omic biomarker signals with an in-house, mobile clinical and neurocognitive assessment battery developed by our leading psychometricians to produce dynamic readouts of patterns related to mechanisms underlying neuropsychiatric disorders. This approach breaks down knowledge silos in academia and industry to generate and validate unique models to bring precision methods to drug/device trials and ultimately enable personalized care protocols.
Sama Therapeutics' low-code/no-code analytics pipelines will be advanced in parallel for FDA “Software as Medical Device” 510(k) and de novo regulatory clearance. We are operationalizing our software both as a stand-alone, hardware-agnostic platform and as an API plug-in with strategic hardware partners. We invite partners to join our mission unlocking brain health through integrative neurotechnology and proven transdiagnostic and “transprognostic” algorithms.